Skip to main content
. 2021 Jul 1;2021:9952743. doi: 10.1155/2021/9952743

Table 1.

Patient characteristics in the MAO-B inhibitor and dopamine agonist group.

MAO-B inhibitors (n = 850) Dopamine agonists (n = 22108)
Proportion of men 58.12 38.23
Age distribution 9.41, 35.53, 39.06, 16 24.07, 30.03, 26.66, 19.24
Proportion with drugs for diabetes (none) 6.12 9.98
Proportion with drugs for hypothyroidism (none) 8.71 12.76
Proportion with drugs for hypertension (none) 11.53 15
Proportion with drugs for atrial fibrillation (none) 42.12 39.37
Proportion with first prescription for the MAO-B inhibitor/dopamine agonist from the specialist 3.88 1
Days observed∗∗ 712, 362, 1, 3789 1733, 1623.5, 1, 3836
Proportion with levodopa prescription dispensed 58.59 6.39
Days until levodopa prescription dispensed∗∗ 352, 187, 1, 2081 621, 315, 1, 3665

Age groups, 50–59, 60–69, 70–79, and 80+. ∗∗Mean, median, min, and max.